We need to investigate the impact of novel CFTR modulating agents on the lung microbiome, and we need to improve and harmonize prophylactic- and treatment strategies for high risk populations (e.g., end stage CF lung disease and CF patients after lung transplantation). The gene discussed is CFTR; the disease is lung disorder.